BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc. is a global biotechnology company founded in 1997, dedicated to developing transformative medicines that address life-threatening genetic conditions. The company has eight marketed products treating conditions such as achondroplasia, severe hemophilia A, and several rare inherited and lysosomal storage diseases. BioMarin is also advancing a strong pipeline of investigational medicines in various clinical and preclinical stages. Their focus on patient communities and collaboration helps improve care and foster a people-first culture within the biotech industry.